Norditropin NordiLet is a pre-filled pen designed to be used with NovoFine disposable needles. The dose is delivered in clicks. Norditropin NordiLet delivers 1-29 clicks in increments of 1 click for each injection.
5 mg/1.5 mL: The dose per click is 0.0667 mg.
10 mg/1.5 mL: The dose per click is 0.1333 mg.
In the package leaflet for each strength a range of doses in mg per number of clicks is given in a conversion table.
The dosage is individual and must always be adjusted in accordance with individual's clinical and biochemical response to therapy. Generally, daily subcutaneous injection in the evening is recommended. The injection site should be varied to prevent lipoatrophy.
For the injection procedure, please see the instruction manual for Norditropin NordiLet 5 mg/1.5 ml or Norditorpin NordiLet 10 mg/1.5 ml.
Patients should be reminded to wash their hands thoroughly with soap and water and/or disinfectant prior to any contact with Norditropin NordiLet.
Norditropin NordiLet should not be shaken vigorously at any time.
General recommendations for dosages are shown as follows.
Children: Growth hormone deficiency: 0.025 to 0.035 mg/kg/day or 0.7 to 1.0 mg/m2/day.
When GHD persists after growth completion, growth hormone treatment should be continued to achieve full somatic adult development including lean body mass and bone mineral accrual.
In children with Turner syndrome: 0.045 to 0.067 mg/kg/day or 1.3 to 2.0 mg/m2/day.
In children with Chronic renal disease: 0.050 mg/kg/day or 1.4 mg/m2/day.
In children born small for gestational age (SGA): 0.033 to 0.067 mg/kg/day or 1.0 to 2.0 mg/m2/day.
Adults: Replacement therapy: The dosage must be adjusted to the need of the individual patient.
In patients with childhood onset GHD, the recommended dose to restart is 0.2-0.5 mg/day with subsequent dose adjustment on the basis of IGF-I concentration determination.
In patients with adult onset GHD, it is recommended to start treatment with a low dose 0.1-0.3 mg/day and to increase the dosage gradually at monthly intervals in order to meet the need of the individual patient. Serum IGF-I can be used as guidance for the dose titration. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement, are under-treated while men are over-treated.
Dose requirements decline with age. Maintenance dosages vary from person to person, but seldom exceed 1.0 mg/day (equal to 3 IU/day).